Cancer Vaccine

About Medigen

Medigen is a preclinical-stage biotech company developing a pipeline of vaccines for significant unmet medical needs, including Chikungunya, Venezuelan Equine Encephalitis (VEE), Lassa fever, and influenza. Its strategy is built on a proprietary vaccine technology platform designed to elicit safe and robust immune responses. The company is expanding its physical footprint for manufacturing and R&D, indicating a transition towards clinical development and potential contract manufacturing capabilities. As a private entity with no marketed products, it remains in a pre-revenue, R&D-intensive phase.

About VLP Therapeutics

VLP Therapeutics is a clinical-stage biotech advancing a novel vaccine platform centered on self-amplifying RNA (saRNA) with modified nucleosides, such as 5-methylcytidine, to improve safety and immunogenicity. The company has a diversified pipeline including COVID-19, malaria, and dengue vaccines, as well as cancer immunotherapies, supported by partnerships and non-dilutive funding from entities like the Gates Foundation. With operations in the US and Japan, VLPT is positioning itself as a player in the next wave of mRNA and replicon vaccine technology, aiming for broader and more durable immune responses.

Therapeutic Areas

Other Cancer Drugs